

Jeromie M Ballreich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8408916/publications.pdf>

Version: 2024-02-01

29
papers

484
citations

759055

12
h-index

713332

21
g-index

29
all docs

29
docs citations

29
times ranked

611
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of reductions in opioid prescribing on opioid use disorder and fatal overdose in the United States: a dynamic Markov model. <i>Addiction</i> , 2022, 117, 969-976.	1.7	7
2	Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis. <i>Value in Health</i> , 2022, 25, 796-802.	0.1	6
3	Coverage of genetic therapies for spinal muscular atrophy across fee-for-service Medicaid programs. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022, 28, 39-47.	0.5	2
4	Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019. <i>JAMA Network Open</i> , 2022, 5, e221117.	2.8	0
5	Estimating & Comparing Greenhouse Gas Emissions for Existing Intramuscular COVID-19 Vaccines and a Novel Thermostable Oral Vaccine. <i>The Journal of Climate Change and Health</i> , 2022, , 100127.	1.4	2
6	Trends of Prescription Drug Manufacturer Rebates in Commercial Health Insurance Plans, 2015-2019. <i>JAMA Health Forum</i> , 2022, 3, e220888.	1.0	2
7	Medicare Spending on Drugs With Accelerated Approval. <i>Annals of Internal Medicine</i> , 2022, 175, 938-944.	2.0	7
8	Economic value of vaccines to address the COVID-19 pandemic: a U.S. cost-effectiveness and budget impact analysis. <i>Journal of Medical Economics</i> , 2021, 24, 1060-1069.	1.0	51
9	The Association Between Drug Approvals and Burden of Disease From 1990 to 2017. <i>Journal of General Internal Medicine</i> , 2021, 36, 3615-3617.	1.3	2
10	Provider and Patient Characteristics of Medicare Beneficiaries Who Are High-Risk for COVID-19 Mortality. <i>Journal of General Internal Medicine</i> , 2021, 36, 2189-2190.	1.3	0
11	Consider expenditure controlsâ€™ impacts on equity. <i>EClinicalMedicine</i> , 2021, 36, 100913.	3.2	0
12	Cost-effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease. <i>International Forum of Allergy and Rhinology</i> , 2021, 11, 1626-1636.	1.5	27
13	Medicare Expenditures of Atezolizumab for a Withdrawn Accelerated Approved Indication. <i>JAMA Oncology</i> , 2021, 7, 1720-1721.	3.4	4
14	Biosimilar uptake of filgrastim and impact on spending in Medicare Part D from 2015 to 2019.. <i>Journal of Clinical Oncology</i> , 2021, 39, 67-67.	0.8	1
15	Allocation of National Institutes of Health Funding by Disease Category in 2008 and 2019. <i>JAMA Network Open</i> , 2021, 4, e2034890.	2.8	27
16	Modeling Mitigation Strategies to Reduce Opioid-Related Morbidity and Mortality in the US. <i>JAMA Network Open</i> , 2020, 3, e2023677.	2.8	24
17	Cost-effectiveness of School Hearing Screening Programs: A Scoping Review. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 162, 826-838.	1.1	15
18	Affording Genetic Therapies in the Medicaid Program. <i>JAMA Pediatrics</i> , 2020, 174, 523.	3.3	3

#	ARTICLE	IF	CITATIONS
19	Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs. PLoS ONE, 2019, 14, e0225109.	1.1	2
20	Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit: Lessons on Cost Sharing from Other US Policy Partnerships Between Government and Commercial Industry. Applied Health Economics and Health Policy, 2018, 16, 753-763.	1.0	2
21	Coverage of Nonpharmacologic Treatments for Low Back Pain Among US Public and Private Insurers. JAMA Network Open, 2018, 1, e183044.	2.8	98
22	Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers. JAMA Network Open, 2018, 1, e180235.	2.8	37
23	Reducing Branded Prescription Drug Prices: A Review of Policy Options. Pharmacotherapy, 2017, 37, 1469-1478.	1.2	10
24	Branded prescription drug spending: a framework to evaluate policy options. Journal of Pharmaceutical Policy and Practice, 2017, 10, 31.	1.1	5
25	Bridging the Silos of Service Delivery for High-Need, High-Cost Individuals. Population Health Management, 2016, 19, 421-428.	0.8	23
26	Does Fracture Care Make Money for the Hospital? An Analysis of Hospital Revenues and Costs for Treatment of Common Fractures. Journal of Orthopaedic Trauma, 2015, 29, e219-e224.	0.7	23
27	Factors associated with high short-acting β_2 -agonist use in urban children with asthma. Annals of Allergy, Asthma and Immunology, 2015, 114, 385-392.	0.5	21
28	Attributes common to programs that successfully treat high-need, high-cost individuals. American Journal of Managed Care, 2015, 21, e597-600.	0.8	43
29	Equitable Access to Care – How the United States Ranks Internationally. New England Journal of Medicine, 2014, 371, 1567-1570.	13.9	40